Article Topic
PSM asks federal agencies to review Hims & Hers’ 2026 Super Bowl ad
On March 10, PSM sent letters to the FDA, FTC, and the Department of Justice asking them to take immediate action to address the ad’s false and misleading promotion of its compounded programs and diagnostic tests.
[...]Cases to watch
PSM watches court cases that have an impact on drug supply chain safety. Click through to these cases to follow along with us.
[...]Case overview: Novartis AG and Genentech v SHARx and Campbell Heights Pharmacy (2026 — ) – ongoing
Novartis and Genentech have filed a Lanham Act complaint against an alternative funding program and a Canadian pharmacy allegedly supplying Canadian Xolair to Michigan patients.
[...]Are dead insects in manufacturing areas enough to disqualify a firm from the FDA’s Green List for makers of GLP-1 API?
Industry experts told us that these two companies are on the FDA’s Green List, despite problematic inspections in late 2024 and early 2025. Learn what the inspectors found.
[...]Prescription Drug Affordability Board Activity, January 2026
Prescription Drug Affordability Board Activity, January 2026 Activities Summary Colorado: At its January meeting, the PDAB discussed ways to improve patient engagement and agreed to accept the dismissal of Amgen v. Mizner. The board’s next meeting will be February 20, 2026. Maryland: Maryland’s next PDAB meeting will be February 23, 2026 at 9:00 AM ET.…
[...]Update on drug importation, February 2026
Well-meaning advocates continue to propose importing medicine from foreign countries to lower drug prices for Americans. Past efforts didn’t pay off financially and raised public health risks. Here’s the state of this issue today.
[...]PSM gives testimony in opposition to a Colorado bill to permit alternative funding programs
On February 17, PSM submitted written and oral testimony in opposition to Colorado HB26-1056, which would permit self-insured employers to use alternative funding programs to import foreign medicines from outside the U.S. drug supply chain.
[...]FDA Alert: Abbott FreeStyle Libre 3 and Libre 3 Plus Continuous Glucose Monitor Recall
The FDA has posted a notice about the recall of continuous glucose monitors from Abbott.
[...]FDA Alert: Dietary supplement recall due to undeclared drug ingredient
The FDA has posted a notice for a dietary supplement recalls involving products found to contain undeclared pharmaceutical ingredients.
[...]Four things Congress should do for patient safety in the rest of the 119th
This post outlines practical steps Congress should take to strengthen pharmaceutical border security, reinforce regulatory oversight, and protect patients.
[...]